ATYR
Company Description
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 190,000 | 235,000 | 353,000 | 10.39M | 0 | 10.46M | 422,000 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (74.12M) | (64.02M) | (50.39M) | (45.34M) | (33.77M) | (16.22M) | (23.60M) | (34.52M) | (48.21M) | (57.85M) | (47.97M) | (24.35M) |
| EPS | -0.80 | -0.86 | -0.94 | -1.60 | -1.77 | -1.77 | -7.03 | -16.13 | -26.16 | -34.20 | -42.42 | -422.73 |
| Free Cash Flow | (62.06M) | (69.18M) | (37.44M) | (43.53M) | (33.27M) | (15.50M) | (20.09M) | (31.66M) | (43.68M) | (53.46M) | N/A | N/A |
| FCF / Share | -0.67 | -0.93 | -0.70 | -1.53 | -1.74 | -1.69 | -5.99 | -14.79 | -23.70 | -31.61 | N/A | N/A |
| Operating CF | (61.99M) | (69.12M) | (33.22M) | (41.89M) | (33.08M) | (15.30M) | (20.01M) | (31.06M) | (42.36M) | (52.86M) | N/A | N/A |
| Total Assets | 94.16M | 96.83M | 120.65M | 95.79M | 115.54M | 38.73M | 36.19M | 52.75M | 89.36M | 80.52M | N/A | N/A |
| Total Debt | 12.03M | 13.28M | 15.10M | 11.53M | 1.38M | 2.24M | 11.73M | 16.03M | 19.73M | 9.54M | N/A | N/A |
| Cash & Equiv | 10.74M | 11.05M | 22.54M | 9.98M | 2.34M | 16.95M | 9.21M | 22.96M | 21.09M | 38.39M | N/A | N/A |
| Book Value | 67.48M | 70.02M | 90.66M | 71.46M | 109.30M | 31.65M | 21.19M | 33.65M | 64.25M | 62.80M | N/A | N/A |
| Return on Equity | -1.10 | -0.91 | -0.56 | -0.63 | -0.31 | -0.51 | -1.11 | -1.03 | -0.75 | -0.92 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 190,000 | 0 | 0 | 0 | 0 | 0 | 235,000 | 0 | 353,000 | 0 |
| Net Income | (10.79M) | (13.96M) | (25.74M) | (19.53M) | (14.88M) | (14.97M) | (17.26M) | (16.31M) | (15.49M) | (14.76M) | (11.34M) | (12.34M) |
| EPS | -0.11 | -0.14 | -0.26 | -0.22 | -0.17 | -0.18 | -0.23 | -0.23 | -0.23 | -0.25 | -0.20 | -0.22 |
| Free Cash Flow | (12.65M) | (12.23M) | (20.51M) | (13.90M) | (15.42M) | (13.16M) | (13.17M) | (20.46M) | (22.40M) | (11.08M) | (10.12M) | (14.40M) |
| FCF / Share | -0.13 | -0.12 | -0.21 | -0.15 | -0.18 | -0.16 | -0.17 | -0.28 | -0.34 | -0.19 | -0.17 | -0.26 |
| Operating CF | (12.52M) | (12.20M) | (20.48M) | (13.89M) | (15.42M) | (13.13M) | (13.16M) | (20.45M) | (22.38M) | (11.06M) | (9.56M) | (12.01M) |
| Total Assets | 79.65M | 94.16M | 106.65M | 101.53M | 97.25M | 96.83M | 91.62M | 105.94M | 113.25M | 120.65M | 125.07M | 132.75M |
| Total Debt | 11.70M | 12.03M | 12.36M | 12.68M | 12.99M | 13.28M | 13.57M | 13.85M | 14.13M | 15.10M | 15.22M | 15.39M |
| Cash & Equiv | 10.01M | 10.74M | 6.15M | 17.22M | 10.36M | 11.05M | 11.46M | 6.80M | 6.81M | 22.54M | 9.79M | 12.31M |
| Book Value | 57.93M | 67.48M | 80.23M | 74.84M | 75.05M | 70.02M | 65.33M | 81.61M | 84.47M | 90.66M | 98.39M | 106.24M |
| Return on Equity | -0.19 | -0.21 | -0.32 | -0.26 | -0.20 | -0.21 | -0.26 | -0.20 | -0.18 | -0.16 | -0.12 | -0.12 |
